Craig-Hallum analyst Matt Hewitt raised his price target for Teladoc to $110 from $80 while maintaining a Buy rating on the shares. The analyst notes that Teladoc has announced it has agreed to acquire InTouch Health, which was followed by a pre-release of Q4 results that were above consensus on the top line. Overall, he came away from these announcements with increased confidence that Teladoc's rapid rate of growth can be sustained - or even accelerate - in the coming quarters. Longer term, Hewitt believes the acquisition of InTouch strengthens Teladoc's position within the provider portion of the market, an area that historically had been less of a focus for the company.